2026-04-29T00:59:55Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/151492025-06-24T16:13:19Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Kissling, Esther author Hooiveld, Mariëtte author Martínez-Baz, Iván author Mazagatos, Clara author William, Naoma author Vilcu, Ana-Maria author Kooijman, Marjolein N author Ilić, Maja author Domegan, Lisa author Machado, Ausenda author de Lusignan, Simon author Lazar, Mihaela author Meijer, Adam author Brytting, Mia author Casado, Itziar author Larrauri, Amparo author Murray, Josephine-L K author Behillil, Sylvie author de Gier, Brechje author Mlinarić, Ivan author O'Donnell, Joan author Rodrigues, Ana Paula author Tsang, Ruby author Timnea, Olivia author de Lange, Marit author Riess, Maximilian author Castilla Catalán, Jesús author Pozo Sanchez, Francisco author Hamilton, Mark author Falchi, Alessandra author Knol, Mirjam J author Kurečić Filipović, Sanja author Dunford, Linda author Guiomar, Raquel author Cogdale, Jade author Cherciu, Carmen author Jansen, Tessa author Enkirch, Theresa author Basile, Luca author Connell, Jeff author Gomez, Verónica author Sandonis-Martin, Virginia author Bacci, Sabrina author Rose, Angela Mc author Pastore Celentano, Lucia author Valenciano, Marta author I-MOVE-COVID-19 author ECDC primary care study teams author Conde-San Román, Patricia author Casas Flecha, Inmaculada author Oliva Dominguez, Jesus Angel author Delgado-Sanz, Concepcion author 2022-05 Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset. Euro Surveill. 2022 May;27(21):2101104. http://hdl.handle.net/20.500.12105/15149 35620997 10.2807/1560-7917.ES.2022.27.21.2101104 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin COVID-19 Delta variant Europe SARS-CoV-2 Multicentre study Test-negative design Vaccine effectiveness Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021